This is a translation of the Swedish press release published 2022-11-10, 08.15 CET

Neola Medical AB (publ) today publishes the Q3 report of 2022 (in Swedish). The report is available at the company’s website and is attached to the press release.

The large clinical study on 100 newborn babies that has been ongoing this year at the University Hospital in Cork, Ireland, was finalized during this quarter thanks to a successful patient recruitment. Positive subgroup results from the first 50 babies was presented at a conference in the U.S.. A preferential rights issue of approximately 55 MSEK was initiated during the quarter to strengthen the company’s finances for upcoming clinical and technical studies. Work towards market approval in Europe and the U.S. started and the organization has been strengthened with clinical and regulatory competence. Moreover, a new patent has been granted which further strengthens the company’s competitiveness.

Read the entire press release (in Swedish) here: Press release (in Swedish)